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aspects of cardio-renal pathophysiology and immunity. Leading scientists from different and related
disciplines of clinical and basic research described and reviewed recent discoveries, and discussed
emerging topics under the headings “Immunity and Renal Pathophysiology”; “Autoimmunity and the
Inﬂammasome”; “Immunity and the Gut Microbiome”; “Immuno-Metabolism”; “Immunogenetics,
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).H ypertension and vascular disease are well-knownassociations and complications of chronic kidney
disease (CKD), and both are major contributors to its
continuing high morbidity and mortality. Although
the association between inﬂammation in CKD and cardio-
vascular disease is broadly recognized, its pathophysio-
logical basis is still unclear, as is the relationship of
inﬂammation in CKD to innate and adaptive immunity.
The pathophysiologies affecting cardiovascular function
and immunity have, until now, been considered very
different and separate ﬁelds of clinical interest and
research; however, increasing evidence indicates that
there is signiﬁcant overlap and interplay between
them. This interdisciplinary symposium focused on
cardio-renal pathophysiology and its links to immu-
nology and inﬂammation, and this meeting report sum-
marizes the main highlights of the meeting and
provides background to some of the related short
review articles that also appear in this issue of Kidney
International Reports. In addition to the keynotespondence: Xiong Z. Ruan, AstraZeneca-Shenzhen University
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016speakers, 69 abstracts were presented orally or as post-
ers. A selection of the presentations can be accessed at
www.theisn.org/education. Figure 1 is a photograph
the organizers and invited participants.
Immunity, Inﬂammation, and Renal
Pathophysiology
Dr Jan-Eric Turner (Universitätsklinikum Hamburg-
Eppendorf, Germany) introduced us to the function of
innate lymphoid cells (ILCs) in tissue injury and repair.
Although these recently described lymphoid cells can be
found in the kidney and are part of the innate immune
system, their activation is antigen-independent. They
include conventional natural killer cells, now termed
“killer” ILCs or “helper-like” ILCs, which can be sub-
divided according to their cytokine proﬁle, transcription
factors, and tissue localization. Important functions for
ILCs in immune barrier protection against various
pathogens in tissues such as gut, lung, and skin have
been identiﬁed, as well as roles in autoimmune inﬂam-
mation in skin and intestine, metabolic control of adi-
pose tissue.1 Interleukin (IL)-5- and IL-13-producing
ILCs are crucial in the regulation of eosinophil number
and differentiation of alternatively activated macro-
phages.2 By producing mediators that directly enhance
epithelial growth, ILCs can contribute to tissue remod-
eling and repair following acute injury. But they can alsoKidney International Reports (2016) 1, 156–165
Figure 1. Group photograph of the meeting organizers and invited speakers.
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by employing similar cytokine pathways. Most ILCs are
GATA-3 positive and long-lasting; however, the role of
ILC subtypes in the kidney as a source of T helper-cell-
associated cytokines and their function in renal inﬂam-
mation and ﬁbrosis requires more study.3
Dr Stephen Alexander (Children’s Hospital at West-
mead, Australia) provided an overview of the interac-
tion of the innate and adaptive or cognate immune
systems in glomerulonephritis (GN). Inﬂammation and
repair in kidney disease are affected by both systems,
with important mechanisms of repair involving regu-
latory T cells. These cells provide protection against
innate immune-mediated (macrophage) kidney injury
and renal impairment in children with cardiac disease,
as well as playing a role in different macrophage and
dendritic cell subsets in various models of GN.4,5
Dr Jeremy Hughes (University of Edinburgh, UK)
provided further insight into the diversity of function
of macrophages beyond the conventional M1/M2
paradigm, suggesting a potentially wider role for these
cells in the response to renal injury and repair.
Macrophage depletion can limit renal injury and scar-
ring, but also impair regeneration and repair. These
cells are involved in GN, diabetic nephropathy, tubu-
lointerstitial ﬁbrosis, acute kidney injury (AKI),
transplant rejection, cystic renal disease, and ischemic
preconditioning, all of which emphasize their impor-
tance in renal pathology.6 Recent studies have alsoKidney International Reports (2016) 1, 156–165highlighted the signiﬁcance of the local tissue micro-
environment: Exposure to chemokines and growth
factors secreted by tubular epithelial cells such as
colony stimulating factor-1, with upregulation of
microRNA-21, can direct macrophage polarization and
limit inﬂammation and facilitate repair. Although this
can expedite resolution of acute injury, it may be less
successful in chronic disease. A deeper understanding
of the induction and control of macrophage activation
and resulting phenotype, as well as the intracellular
signaling pathways that regulate macrophage re-
sponses, and mediators involved in the cross-talk be-
tween macrophages and parenchymal cells, will lead to
new therapeutic options in renal disease.
Dr Kunling Ma (Southeast University, China) dis-
cussed the contribution of increased circulating platelet
microparticles, the most abundant microparticle sub-
type,7 to glomerular endothelial injury in diabetic ne-
phropathy. The release of platelet microparticles is
thought to be proinﬂammatory, eliciting a cytokine
response. Platelet microparticles may be useful bio-
markers of endothelial injury, as well as suitable targets
for treatment in diabetes.
Autoimmunity and the Inﬂammasome
Dr Minghui Zhao (Peking University First Hospital,
China) discussed small vessel antineutrophil cytoplasmic
antibody-associated vasculitis and immunity. The ma-
jority of patients in China with antibody-associated157
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plasmic antibody positive microscopic polyangiitis,
which is more common in elderly persons and typically
affects the kidneys as pauci-immune crescentic GN.
Activation of complement via the alternative pathway
has been shown to be critical, particularly the interac-
tion between C5a and its receptor CD88 (C5aR), pro-
ducing an ampliﬁcation loop for neutrophil recruitment
and activation that involves sphingosine-1-phosphate
signaling8; mice lacking C5aR are protected from anti-
neutrophil cytoplasmic antibody-related GN, and C5a
in vitro primes neutrophils for an antineutrophil cyto-
plasmic antibody-induced oxidative burst and degran-
ulation. A small molecule antagonist of C5aR, CCX168, is
currently in clinical trials.
Dr Felix Knauf (University of Erlangen-Nürnberg,
Germany) provided a renal perspective on the inﬂam-
masome. Inﬂammasomes are part of the innate immune
system and are signaling platforms assembled in
response to microbe-speciﬁc, as well as nonmicrobial,
antigens. On activation, proinﬂammatory cytokines
such as IL-1 and IL-18 are released that engage immune
defenses to trigger an inﬂammatory form of cell
death termed pyroptosis.9 He reviewed current
knowledge of the role of the inﬂammasome in the
pathogenesis of some forms of kidney injury and
disease.10 Crystalopathies are particular examples of
NLRP3 inﬂammasome-mediated injury and crystal
(urate or oxalate) deposition in the kidney can cause
both acute and chronic kidney injury.11
Dr Chuan Wu (Brigham and Women’s Hospital and
Harvard Medical School, USA) discussed the regulation
of T helper 17 cells and a link with salt sensing and
serum glucocorticoid kinase-1 signaling via IL-23 and
its receptor (IL-23R). IL-23R is also associated with
inﬂammatory autoimmune disease, particularly in the
intestine. In a T cell-dependent model of colitis, serum
glucocorticoid kinase-1 promotes inﬂammatory T
helper 17 cells and inhibits Foxp3þ regulatory T
cells.12 Serum glucocorticoid kinase-1 regulates IL-23R
expression, which in turn maintains T helper 17 cell
function. This illustrates an important role for serum
glucocorticoid kinase-1 in the interplay between T
helper 17 effector cells and Foxp3þ regulatory T cells
in inﬂammatory bowel disease.
Dr Dan Liu (Zhong Da Hospital, China) considered the
role of albuminuria in the development and progression
of CKD by promoting tubulointerstitial inﬂammation and
ﬁbrosis and discussed the part played by megalin or
cubilin-mediated albumin uptake, its transfer into lyso-
somes, and the link to tubular cell activation of the
NLRP3 inﬂammasome and tubulointerstitial inﬂamma-
tion. Silencing of megalin or cubilin expression was
shown to inhibit albumin-induced NLRP3 activation as a158result of lysosomal leakage of hydrolases, such as
cathepsin B, when tubular epithelial cells are exposed
to excess albumin.13
Dr Rujun Gong (Nanjing Drum Tower Hospital,
China) talked about glycogen synthase kinase 3b
(initially identiﬁed as an inactivator of glycogen
synthase) inhibition, which can promote macrophage
polarization and reduce inﬂammation and acute and
chronic kidney damage following AKI. Gong’s group
has shown that inhibition of glycogen synthase kinase
3b by TDZD-8, a selective inhibitor, reduces kidney
inﬂammation and injury in AKI by regulating macro-
phage recruitment and polarization. Recent studies
demonstrated that systemic administration of a small
molecule glycogen synthase kinase 3b inhibitor given
before and 36 hours after AKI signiﬁcantly attenuated
renal inﬂammation. Kidney macrophage inﬁltration was
also reduced, and switching from a proinﬂammatory
M1 to an anti-inﬂammatory M2 phenotype was pro-
moted. These changes were associated with less tissue
injury and more rapid recovery of renal function, with
fewer histologic features of AKI and less ﬁbrosis.14
Dr Fan Yi (Shandong University, China) reported on
a podocyte-speciﬁc knockout of Sirtuin-6 (SIRT6)
(a deacetylase with anti-inﬂammatory properties) that
leads to more renal injury in a rat model of diabetic
nephropathy by heightening inﬂammation. Dr Yi has
shown that high glucose selectively down-regulates
SIRT6 expression in podocytes, rather than in
glomerular endothelial or mesangial cells, or in tubular
epithelial cells. In vivo, podocyte-speciﬁc knockout of
SIRT6 aggravated podocyte dysfunction and enhanced
the inﬂammatory response. In vitro, overexpression of
SIRT6 restored reduced nephrin expression caused by
high glucose. SIRT6 can also decrease NLRP3 inﬂam-
masome activation by selectively inhibiting Notch 1
signaling, indicating a role for SIRT6 in hyperglycemia-
induced podocyte injury.
Immunity and the Gut Microbiome
Dr Liping Zhao (Shanghai Jiao Tong University, China)
gave an overview of the relationship between changes
in the gut microbiota and chronic inﬂammation due to
bacterial endotoxins. Zhao reported that the endotoxin-
producing bacterium Enterobacter cloacae B29 isolated
from the gut of morbidly obese humans caused an
obesity phenotype with increased adiposity, systemic
inﬂammation, and insulin resistance in germ-free mice.
Speciﬁc types of gut microbiota have the genetic po-
tential to contribute to the development of metabolic
disease.15 Proﬁling of urinary metabolites from bacteria
by nuclear magnetic resonance and mass spectrometry
can be correlated with the gut microbiome. Using this
approach in the dietary treatment of patients withKidney International Reports (2016) 1, 156–165
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obesity), Zhao has compiled and correlated 100 draft
genomes of prevalent gut bacteria from a large meta-
genomic dataset, and identiﬁed bacteria with enzymes
that convert choline to trimethylamine. Trimethyl-
amine is metabolized in the liver to trimethylamine
N-oxide and is a recognized uremic toxin linked to
atherogenesis and increased cardiovascular morbidity
and mortality.16 The signiﬁcance and role of the gut
microbiome in chronic metabolic diseases is just
emerging.
Dr Gregory F. Sonnenberg (Weill Cornell Medicine,
USA) discussed the immune system and its critical role
in protecting against infection from pathogenic or-
ganisms. However, studies in patients indicate that
abnormal host immune responses to the commensal gut
bacteria that normally colonize the body’s barrier
surfaces are causally linked to the pathogenesis and
progression of several chronic infectious, and inﬂam-
matory and metabolic diseases, including HIV, inﬂam-
matory bowel disease, and cancer. Using advanced
immunologic and microbiologic approaches to interro-
gate the relationship between the mammalian immune
system and intestinal commensal bacteria, Sonnenberg
identiﬁed a critical role for ILCs in orchestrating the
host relationship to deﬁned subsets of commensal
bacteria.17,18 Delineating these complex interactions
will provide a better understanding of the pathogenesis
of multiple chronic inﬂammatory diseases and help in
developing novel therapeutic strategies that target
commensal bacteria-dependent chronic inﬂammation.
Dr Frank J. Gonzalez (National Cancer Institute,
USA) discussed the gut microbiome in the context of
obesity and fatty liver disease (nonalcoholic steatohe-
patitis), describing effects of the gut microbiota on host
bile acid composition and hepatic and intestinal farse-
noid X receptor (FXR) signaling. Bile acid metabolism is
tightly linked to intestinal and hepatic FXR signaling,
and FXR plays an important role in the regulation of
bile acid synthesis and transport, and hepatic de novo
lipogenesis. Manipulation of the gut microbiota in mice
to increase the Lactobacillus population, which metab-
olize the endogenous FXR antagonist tauro-b-mur-
icholic acid, is correlated with inhibition or resolution
of obesity, decreased insulin resistance, and reduced
nonalcoholic steatohepatitis.19 Intestine-speciﬁc FXR-
null mice showed that the gut microbiome acts by
regulating the bile acid-intestinal FXR-ceramide axis to
alter serum ceramide levels, which in turn affect adi-
pose tissue and the liver to decrease weight, insulin
resistance, and hepatic lipid levels.20 These studies
have revealed a new target and potential lead com-
pounds for nonalcoholic steatohepatitis and the treat-
ment of metabolic disease.Kidney International Reports (2016) 1, 156–165Immuno-Metabolism
Dr Hans Stauss (University College London, UK)
addressed the importance of modulating activity of the
key cell growth and metabolism mechanistic target of
rapamycin pathway to control T cell function for
immunotherapy in cancer. The design of translational
strategies for generating heterogeneous T cell immu-
nity against cancer allows for up-regulation, as well as
inhibition of the mechanistic target of rapamycin
complex 1 pathway, and can be highly selective for
therapeutic T cells without affecting systemic mecha-
nistic target of rapamycin complex 1 functions.21
Dr Youfei Guan (Dalian Medical University, China)
gave an overview of prostaglandin E2’s role in the
regulation of immunity and inﬂammation. Prosta-
glandin E2 also has a speciﬁc inﬂuence on CD4þ T
cells: It inhibits the production of the T helper 1
cytokine interferon-g but increases T helper 2 cyto-
kines such as IL-4, IL-5, and IL-13. Prostaglandin E2
shifts the balance away from T helper 1 toward T
helper 2, favoring chronic infection and allergic dis-
eases.22 A better understanding of the biological ac-
tions of prostaglandin E2 and its receptors, and signal
pathways, in innate and adaptive immunity should
facilitate the development of molecular inhibitors or
activators for the treatment of infectious and inﬂam-
matory diseases, including renal inﬂammation.
Dr Morgan Fullerton (McMaster University, Canada)
discussed the role of adenosine monophosphate-
activated protein kinase (AMPK) in inﬂammation and
metabolism in obesity. A model in which the b1 sub-
unit of AMPK is deleted reveals an anti-inﬂammatory,
insulin-sensitizing role for AMPK b1 in obesity, and
that AMPK b1 protects macrophages from lipid-
induced inﬂammation.23 Such studies have also
shown that salicylate is an AMPK activator by binding
to AMPK b124 and that macrophage AMPK is anti-
atherogenic. These ﬁndings highlight the therapeutic
potential of targeting macrophage AMPK with new
or existing drugs to restore lipid homeostasis and
resolve inﬂammation during the early stages of obesity-
induced metabolic dysfunction.
Immunogenetics, Transcriptomics, and
Epigenetics
Dr Xueqing Yu (Sun Yat-sen University, China) talked
about the genetic susceptibility to lupus nephritis,
which is more common in Asian and African patients
with systemic lupus erythematosus (51%–55%
compared with 14% in whites), and has a strong
association with a major histocompatibility complex
class II gene cluster region on chromosome 6. Yu’s
group did a deep sequencing analysis of the major
histocompatibility complex region and the protein159
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lupus nephritis. They discovered 5 independent risk
variants within the major histocompatibility complex
region, as well as 3 nonmajor histocompatibility com-
plex risk loci with genome-wide signiﬁcance; in addi-
tion, they also discovered another 2 novel loci with
suggestive associations. Of the 6 single-nucleotide
polymorphisms, 4 single-nucleotide polymorphisms
are novel susceptibility loci for lupus nephritis, and the
other 2 are within the reported systemic lupus ery-
thematosus loci. The genes located at these newly
associated loci implicate altered function in the modu-
lation of sex hormones, the epidermal growth factor
receptor network, and CD4þ T cell signaling. About
16.2% of the phenotypic variance can be explained by
all 10 susceptibility variants discovered in these lupus
nephritis samples.25
Dr Jun Wang (Shenzhen Beijing Genome Institute,
China) provided a general overview of the million ge-
nomes project at the Beijing Genome Institute. The
original Human Genome Project and later 1000 Genome
Project demonstrated the power of the context and
variation catalog of genetics, and showed the impor-
tance of genetic variation in disease. However, much
larger datasets are needed to resolve and extend this
knowledge with a view to developing personalized or
precision medicine.
Dr Joakim Lundeberg (Science for Life Laboratory,
Sweden) discussed the innovative and novel technique
that his group has developed of transcriptomic or
spatial imaging. They have devised a simple strategy
that makes it possible to carry out global gene
expression analysis in histologic tissue sections,
matching the tissue transcriptome with the underlying
histologic structure and features at a current resolution
of 100 mm, and aiming eventually for 30 mm. Moni-
toring of all cells in a tissue section individually by
digital RNA sequencing will reshape our basic under-
standing of cell circuitry and will have profound
consequences for our understanding of complex sub-
jects such as tissue differentiation and proliferation, the
causes of cancer, organogenesis, and the responses to
tissue injury, and also provide new diagnostic insights.
Striking (as yet unpublished) examples in prostate
cancer and in cardiac development were presented.
Dr Peter Maxwell (Queen’s University of Belfast, UK)
discussed the importance of epigenetics in diabetic
kidney disease, which is known to have an inherited
susceptibility that probably underlies the familial
clustering of nephropathy and the differences in
prevalence of kidney disease in different ethnic pop-
ulations. Epigenetics refers to heritable (transgenera-
tional) or dynamic changes in gene expression resulting
from factors other than a direct change in the DNA160sequence of the genome. These modiﬁcations may be
inherited or occur in response to current or past
environmental exposures such as diet, drugs, or illness.
Epigenetic mechanisms may include chromatin
remodeling, altered DNA methylation, or changes in
the expression of speciﬁc microRNAs. Extreme envi-
ronmental stress may result in long-term epigenetic
modiﬁcation of the genome with an increased lifetime
risk of diabetes, cardiovascular disease, or CKD.26
Altered metabolic states, such as hyperglycemia in
diabetes, may lead to changes in gene expression
mediated by epigenetic mechanisms and this has been
referred to as hyperglycemic memory.27 Epigenetic
biomarkers could prove useful in stratifying in-
dividuals at higher risk of developing diabetic kidney
disease. Epigenetic features are also attractive thera-
peutic targets, because they may be amenable to
alteration or reversal, offering potential for drugs that
can selectively target epigenetic changes in particular
tissues and cell types.
Dr Assam El-Osta (Baker IDI Heart and Diabetes
Institute, Australia) discussed DNA methylation and
sequencing that identiﬁes CTCF (an enhancer blocking
protein) regulated genes implicated in diabetic com-
plications. Genetic variability cannot explain why
some individuals and some families seem programmed
to have a high rate of complications.28 El-Osta dis-
cussed the Finnish Diabetic Nephropathy (FinnDiane)
Study result suggesting that speciﬁc epigenetic events
contribute to programming for the development and
progression of diabetes complications.
Immunity and Hypertension
Dr Bernard Rossier (University of Lausanne,
Switzerland) delivered the opening lecture on evolu-
tionary medicine and the hypertension pandemic. He
emphasized the critical role of the renin-angiotensin-
aldosterone-system (RAAS) in salt conservation dur-
ing evolution in vertebrates, and in the control of blood
pressure, and focused on the importance of genetic and
environmental factors in explaining the variability of
the blood pressure trait.29 He also discussed the gene-
culture-environment mismatch hypothesis as the basis
of the hypertension pandemic, and why evolutionary
medicine is an important and emerging ﬁeld with po-
tential to identify new diagnostic tests, drug targets,
and therapies.30
Dr Jens Titze (Vanderbilt-University, USA, and
University of Erlangen-Nürnberg, Germany) discussed
gut-kidney interactions, metabolism, and ﬂuid and
electrolyte homeostasis. Investigation of salt and water
balance traditionally relies on short-term studies of
bodily responses to extremes in salt intake. Ultra-long-
term sodium balance studies suggest that steady-stateKidney International Reports (2016) 1, 156–165
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vascular storage and release of sodium from the body,
particularly skin and muscle. Experimental work has
revealed that sodium storage is dependent on
lymphatic regulation, and recent data show that so-
dium storage can be imaged and quantiﬁed in vivo in
humans using sodium MRI. A novel link toward a
better understanding of the relationship between renal
and cardiovascular disease could be that sodium stor-
age in tissue leads to urea production in the liver and
extra-renal tissues, which couples sodium metabolism
to urea metabolism. Body sodium content in humans
and animals is not constant, does not always readily
equilibrate with water, and is not exclusively
controlled by the kidney.31 This different view of so-
dium balance provides new research avenues for basic
and clinical investigation.
Dr Matthew Bailey (University of Edinburgh, UK)
discussed autonomic regulation of the immune system
and its implications for blood pressure control and
hypertension. Hypertension is still a major modiﬁable
risk factor for cardiovascular disease and CKD, yet for
many affected individuals, despite treatment compli-
ance, blood pressure control is inadequate. Chronic
activation of RAAS enhances sympathetic tone, which
in turn directly enhances the immune response. Any
single component of the neuro-immune-endocrine axis
may initiate hypertension. When acting in concert, the
progression of cardiovascular or renal disease is accel-
erated.32 He reviewed the major studies in this area to
establish points of convergence between the autonomic
nervous system, the immune system, and RAAS. He
also illustrated a novel contribution from macrophages
to blood pressure homeostasis. Unraveling the complex
biology of the neuro-immune-endocrine axis is chal-
lenging, but it is likely to improve our understanding
of hypertension and offer more mechanism-based
therapies to control blood pressure.
Dr Tianxin Yang (Sun Yat-sen University, China)
discussed the (Pro)renin receptor (PRR) and blood
pressure control. PRR was cloned around 10 years ago
and is an inactive precursor of prorenin, as well as an
endocrine hormone and component of RAAS. PRR
binding to prorenin activates nonproteolytically an
angiotensin II-dependent pathway, but also a PRR-
dependent (and angiotensin II-independent) signaling
pathway. PRR may play an important role in blood
pressure regulation and cardiovascular function
through its effect on local RAAS activity in various
tissues, including the brain, the vasculature, and the
kidneys.33 Central PRR has been shown to affect
sympathetic outﬂow mediating the hypertension
induced by angiotensin II and deoxycorticosterone
acetate–salt. Mice with overexpression of human PRRKidney International Reports (2016) 1, 156–165in the vasculature have an elevated blood pressure.
Unpublished data support a direct role for the renal
PRR in promoting sodium and water reabsorption.34
PRR may play an important part in the pathogenesis
of hypertension and might offer a new therapeutic
target in hypertension.35
Dr Yanfei Qi (University of Florida, USA) from
Mohan Raizada’s group provided a summary of neuro-
immune communication in hypertension and obesity.
Resistant hypertension is thought to be primarily
neurogenic in origin and characterized by a dysfunc-
tional autonomic nervous system with heightened in-
ﬂammatory and neuro-inﬂammatory proﬁles. Raizada’s
group has proposed that brain–bone marrow commu-
nication is critical in the maintenance of vascular repair
and the inﬂammatory status of the cardiovascular sys-
tem. An autonomic-mediated increase in sympathetic
nerve activity to the bone marrow impairs this balance,
resulting in increased production of proinﬂammatory
progenitor cells and a decrease in angiogenic progenitor
cells. This increases peripheral inﬂammation and com-
promises vascular repair, both hallmarks of hyperten-
sion.36 Furthermore, some of the proinﬂammatory
progenitor cells migrate into autonomic brain regions,
differentiate into activated microglia, and contribute to
neuroinﬂammation. Neuroinﬂammation-induced release
of cytokines, chemokines, and reactive oxygen species
enhances autonomic neuronal activity. This perpetual
cycle of increased sympathetic nerve activity, proin-
ﬂammatory progenitors, and neuroinﬂammation is
critical in driving resistant hypertension.37 Centrally
administered minocycline can dampen neuro-
inﬂammation and may be the basis for development of
more selective drugs to treat resistant hypertension.38
Dr Alicia McDonough (University of Southern Cali-
fornia, USA) discussed the importance of proximal
tubular sodium transport in the regulation of extra-
cellular ﬂuid volume and blood pressure. Excessive
sodium input can acutely increase extracellular ﬂuid
volume and blood pressure, but the kidneys normally
excrete enough sodium and water to normalize blood
pressure, a response known as pressure natriuresis. The
molecular mechanisms underlying the interdependence
of blood pressure and extracellular ﬂuid volume
converge on the regulation of nephron sodium trans-
porters. Angiotensin II-dependent hypertension is
associated with cytotoxic T cell inﬁltration of the
kidneys; these cells secrete IL-17A and interferon-g
that oppose the down-regulation of sodium hydrogen
exchanger isoform 3 and sodium-dependent phosphate
cotransporter.39 Female rodents have a lower set point
for pressure natriuresis that is also due to a relative
redistribution and depression of sodium hydrogen
exchanger isoform 3 and sodium-dependent phosphate161
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is blunted during hypertension may provide new ways
of affecting blood pressure control.40
Dr Zhiming Zhu (Third Military Medical University,
China) focused on the likely role of transient receptor
potential (TRP) channels in intracellular calcium regu-
lation and vascular tone in hypertension. Mammalian
TRP channels can be divided into 6 subfamilies,
including transient receptor potential cation channels,
TRP vanilloid, and TRP melastatin among others.
Increased transient receptor potential cation channels 3
(TRPC3) and transient receptor potential cation chan-
nels 5 (TRPC5) channel protein expression is found in
circulating monocytes of patients with essential hy-
pertension, and in vascular smooth muscle cells from
spontaneously hypertensive rats, and is associated with
increased cell calcium inﬂux.41 In contrast, activation
of TRPV1, present in the endothelium and linked to
nitric oxide release, and TRPM8 cause vasodilatation
and lower blood pressure.42 Agonist actions at these
TRP channels may underlie the cardiovascular beneﬁt
of foods containing capsaicin (TRPV1) or menthol
(TRPM8). An imbalance in TRP channel function may
contribute to the pathogenesis of hypertension, and
these channels might be suitable drug targets for car-
diovascular disease and hypertension.43
Dr Andrew Newby (University of Bristol, UK)
considered macrophage activation and atherogenesis.
Macrophages are found at all stages of human and
experimental atherosclerosis and deleting them can
reduce atheroma in animal models. Although smooth
muscle cells can adopt a macrophage-like phenotype
when exposed to oxidized low-density lipoprotein,
monocyte-derived macrophages are the major players
in foam cell formation and plaque progression, and this
is supported by a positive correlation between the
number of circulating monocytes and susceptibility to
atherosclerosis. Although the so-called M1 macrophage
phenotype seems to promote plaque rupture and
myocardial infarction, the important mediators of
macrophage activation remain unclear, which is a
barrier to ﬁnding better and more selective treat-
ments.44 He presented new data on the importance of
foam cell formation from lipid accumulation, and the
role of acquired and innate immunity in atherogenesis,
but emphasized the limitations in identifying precise
mediators in human atherosclerosis and in animal
models. Production of matrix degrading enzymes, and
the importance of their transcriptomic and epigenetic
regulation, is becoming evident from population
studies, and a key feature linking macrophage activa-
tion to plaque instability. Targeting macrophage acti-
vation is a therapeutic goal in preventing stroke and
myocardial infarction.162Dr Entai Hou (Xi’an Jiaotong University, China)
described the role of fumarase, a mitochondrial and
cytosolic enzyme involved in the tricarboxylic acid
cycle and amino acid metabolism, respectively, and its
role in salt-sensitive hypertension. High-salt loading
limits arginine availability for nitric oxide synthase,
and, thus, nitric oxide production (from arginine
metabolism to citrulline) is reduced in the kidney
because of its restricted capacity to regenerate endog-
enous arginine via the citrulline-nitric oxide pathway.
Fumarase activity is signiﬁcantly lower in the kidneys
of Dahl salt-sensitive rats compared with (consomic)
control SS-13BN rats.45 In studies, fumarase activity
contributed to the reduced arginine synthesis for nitric
oxide production and the blood pressure elevation in
Dahl salt-sensitive rats challenged with high salt.
Immunity, Fibrosis, and Kidney Disease
Dr Richard Kitching (Monash University, Australia)
discussed the role of dendritic cells in CKD and ﬁbrosis.
Although it is attractive to view ﬁbrosis as the ﬁnal
common pathway leading to end-stage renal disease,
the drivers of persistent and progressive renal disease
are many and varied. Active inﬂammatory and meta-
bolic factors accelerate ﬁbrosis and determine pro-
gressive ﬁbrotic disease, but when chronic injury is
advanced, ﬁbrosis still tends to progress even without
an ongoing stimulus. Current evidence suggests that
macrophages can promote progression in antigen-
independent renal ﬁbrosis, whereas the role of inter-
stitial dendritic cells is less clear.46
Dr Karl E. Kadler (University of Manchester, UK)
presented the concept of the circadian clock in matrix
synthesis in ﬁbrosis and the illustrative example of
tendon biology. Although ﬁbrosis due to ectopic
deposition of type I collagen is a recognized feature of
many chronic diseases, the molecular mechanisms of
collagen ﬁbril formation are still unclear, in part
because large and insoluble collagen ﬁbrils are re-
fractory to conventional biochemical or molecular
analysis. The highly organized 3-dimensional matrix in
tendon is an ideal model for studying all stages and
timing of collagen ﬁbrillogenesis, and ﬁndings from
studying tendons may also be applicable to renal
ﬁbrosis. Kadler’s group has used serial block face-
scanning electron microscopy to investigate collagen
ﬁbrillogenesis in vivo.47 This technique can be used to
obtain high-resolution images of cells synthesizing
collagen ﬁbrils at sites on the plasma membrane, which
has led to a 2-stage model of ﬁbrous tissue expansion.48
His group has also shown that the tendon is a
peripheral clock tissue in which the expression of 750
genes is regulated on a 24-hour rhythm.49 Disruption of
the tendon clock, and some identiﬁed key regulatoryKidney International Reports (2016) 1, 156–165
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ﬁbrosis.
Dr Youhua Liu (Southern Medical University, China)
discussed epithelial-mesenchymal communication in
ﬁbroblast activation and kidney ﬁbrosis. Fibroblasts
are the cells responsible for excessive production of
extracellular matrix, and the tubular epithelium is
often the main target of kidney injury. How an injured
tubular epithelium communicates with interstitial
ﬁbroblasts and causes them to undergo phenotypic
activation is a central question. Liu’s group recently
discovered a critical role for sonic hedgehog and Wnt
signaling in mediating an epithelial-mesenchymal
communication in renal ﬁbrogenesis.50 In ﬁbrotic kid-
neys, sonic hedgehog is induced in tubular epithelium,
but not in ﬁbroblasts. However, when sonic hedgehog
is induced in ﬁbroblasts it causes their proliferation
and activation.51 When sonic hedgehog is active in
ﬁbroblasts, these cells secrete a variety of Wnt ligands
that lead to b-catenin activation in the tubular
epithelium. Tubular Wnt/b-catenin activation in turn
induces a wide range of ﬁbrogenic genes, including all
components of the RAAS system.52 These results sug-
gest that sonic hedgehog and Wnt/b-catenin pathways
can mediate bidirectional communication between the
tubular epithelium and interstitial ﬁbroblasts.
Dr Huiyao Lan (Chinese University of Hong Kong,
China) talked about the TGF-b/Smad signaling pathway
in kidney and cardiovascular disease. Lan’s group has
found that in hypertension, angiotensin II is able to
activate the transforming growth factor-b/Smad
signaling pathway via transforming growth factor-b-
dependent and -independent mechanisms.53 Trans-
forming growth factor-b/Smad3 signaling may be a key
pathway in cardio-renal ﬁbrosis, and increasing Smad7
or microRNA-29 expression may be a valid therapeutic
approach.54
Dr Mark Okusa (University of Virginia, USA)
described sphingolipid signaling in kidney disease.
Sphingosine 1-phosphate is the product of sphingosine
phosphorylation by 2 sphingosine kinase (SphK) iso-
forms (SphK1 and SphK2). Localization of SphK1
near the plasma membrane provides sphingosine
1-phosphate, which is exported out of the cell by ABC
transporters and spinster homolog 2, where it can bind
to its 5 different G-protein coupled receptors (sphingo-
sine 1-phosphate 1–5). SphK1 promotes cell survival and
proliferation, and regulates cell transformation. Less is
known about SphK2, but several reports suggest that
SphK2 may have proapoptotic functions.55 Dr Okusa
discussed the role of the sphingolipid pathway in AKI,
repair, and ﬁbrosis. Sphingosine 1-phosphate 1, sphin-
gosine 1-phosphate 3, and SphK2 may be new thera-
peutic targets for AKI and progressive kidney disease.56Kidney International Reports (2016) 1, 156–165Dr Jun Ni (Chinese University of Hong Kong, China)
discussed the ﬁnding that angiotensin-converting
enzyme 2 (ACE2)/angiotensin 1-7 (Ang 1-7)/Mas
receptor (Mas) deﬁciency can promote angiotensin
II-related renal ﬁbrosis by enhancing ERK1/2-MAPK-
Smad3 crosstalk. Ni provided evidence for the ACE2/
Ang1-7/Mas axis having a protective role in CKD by
countering the effects of angiotensin II through its AT1
receptor. They have found that deletion of ACE2 or
Mas in mice causes high blood, which is even higher
following angiotensin II infusion in double knockouts.
Compared with single ACE2 or Mas knockouts, double
knockouts develop more severe hypertensive kidney
injury, including markers of renal ﬁbrosis. Disruption
of the ACE2/Ang1-7/Mas axis enhances AT1 receptor-
dependent ERK/MAPK-Smad3 signaling.
Dr Yi Guan (Huashan Hospital, China) reported on
nicotinamide mononucleotide, a key intermediate in
nicotinamide adenine dinucleotide biosynthesis, which
can rescue the age-related susceptibility to cisplatin-
induced AKI. This effect involves SIRT1 activation,
which is a nicotinamide adenine dinucleotide
biosynthesis-dependent deacetylase, linking nicotin-
amide mononucleotide supplementation to its protec-
tive effect. Studies have shown that in the aging
kidney nicotinamide adenine dinucleotide biosynthesis
levels and SIRT1 expression are both reduced, which
may underlie the more general age-associated increase
in the risk of AKI. Giving nicotinamide mono-
nucleotide, a metabolite of the lipid-lowering drug
niacin, may have a preventative role in managing pa-
tients at high risk of cisplatin-induced AKI, but
perhaps also more generally.
Dr Weidong Wang (Sun Yat-sen University, China)
discussed dual activation of the insulin-sensitizing bile
acid receptors, nuclear receptor FXR (see earlier) and
G-protein-coupled receptor TGR5, which together can
attenuate lithium-induced nephrogenic diabetes insip-
idus. Wang’s group has used INT-767, a dual FXR and
TGR5 agonist, and INT-747, an FXR agonist, in lithium-
induced nephrogenic diabetes insipidus; INT-767, but
not INT-747, prevented the lithium-induced decrease
in urine osmolality and increase in urine output. INT-
767 also attenuated lithium-induced down-regulation
of the aquaporin-2 protein, and mRNA expression of
aquaporin-2, V2R, FXR, and TGR5 in the kidney inner
medulla. In primary cell cultures of rat inner medulla
collecting duct, INT-767 increased aquaporin-2 protein
expression in control and lithium-treated rats, whereas
INT-747 increased aquaporin-2 expression in control
rats only. Activation of both FXR and TGR5 in the
kidney can affect water transport and prevent lithium-
induced nephrogenic diabetes insipidus, the latter
mainly via TGR5 activation.163
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described the effects of targeted deletion of NUMB,
which encodes the ubiquitous adaptor protein Numb,
involved in many cellular functions, including cell fate,
adhesion, migration, and proliferation. It is expressed
in the renal tubule and glomerulus and attenuates
interstitial ﬁbrosis by mitigating G2/M cell cycle arrest
when deleted in proximal tubular cells. Studies in a
knockout mouse model reveal that Numb may be yet
another target in treating tubulointerstitial ﬁbrosis.
Conclusion
International Society of Nephrology Forefronts Sym-
posia are intended to educate and inform, and to
broaden and advance basic and applied renal science
by drawing on expertise from diverse ﬁelds of biology
and clinical medicine. As can be seen from the breadth
of subjects covered in the summaries listed above, we
believe these goals were achieved. In addition, it was a
unique opportunity to bring research scientists,
clinical scientists, and nephrologists from Asia
(speciﬁcally China), Australia, Europe, and North
America together in such a closely interactive format
(Figure 1). The 2015 International Society of
Nephrology Forefronts Symposium in Shenzhen
attracted more than 200 active scientists—senior and
junior—and has, and will, lead to new exchanges and
productive collaborations to innovate in nephrology
research and improve clinical practice.
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